RecallRadar

FDA Drug recall D-0482-2021

Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) 100 mcg/62.5 mcg/25 mcg

On 2021-06-02 the FDA classified a Class II recall of Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) 100 mcg/62.5 mcg/25 mcg by Cardinal Health, citing CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0482-2021
ClassificationClass II
Statusterminated
Initiated2021-03-15
Published2021-06-02
Last updated2026-09-13 11:52 UTC
CompanyCardinal Health
DistributionFL, GA, SC

Product

Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) 100 mcg/62.5 mcg/25 mcg; 1 ELLIPTA Inhaler containing 30 doses (60 blisters total) Rx Only NDC 0173-0887-10 GlaxoSmithKline Research Triangle Park, NC 27709

Reason

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Identifiers

ndc0173-0887-10
ndc0173-0887-14
ndc0173-0887-61
ndc0173-0893-10
ndc0173-0893-14
ndc0173-0893-61
code_info3X8P

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0482-2021%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.